Clinical Trials
32 trialsNCT02123758 2026-05-08
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 1 Active not recruiting
NCT04577833 2026-05-08
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04662580 2026-05-08
ARX517
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05818683 2026-05-08
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT02913196 2026-04-20
Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC
Weill Medical College of Cornell University
Phase 1 Completed
NCT06421935 2026-03-24
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
EMD Serono
Phase 1 Active not recruiting
NCT04477512 2025-11-12
Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
Washington University School of Medicine
Phase 1 Completed
NCT05276492 2025-10-03
Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.
University of Chicago
Phase 1 Terminated
NCT04666129 2025-08-17
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT05413421 2025-08-11
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
ORIC Pharmaceuticals
Phase 1 Recruiting
NCT01792687 2025-03-04
Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate
Aragon Pharmaceuticals, Inc.
Phase 1 Completed
NCT04421222 2025-02-28
EPI-7386
ESSA Pharmaceuticals
Phase 1 Terminated
NCT05295927 2025-02-03
A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)
Janssen Research & Development, LLC
Phase 1 Terminated
NCT04291664 2024-10-17
PK and Dose Escalation and Expansion Study of DST-2970
DisperSol Technologies, LLC
Phase 1 Terminated
NCT06014853 2024-02-05
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects
Bukwang Pharmaceutical
Phase 1 Completed
NCT06193993 2024-01-08
Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients
National University Hospital, Singapore
Phase 1 Active not recruiting
NCT04628988 2023-09-13
A Study of CC-90011 and Comparators in Participants With Prostate Cancer
Celgene
Phase 1 Completed
NCT04179396 2023-06-29
RAMP
pharmaand GmbH
Phase 1 Completed
NCT02740985 2023-05-26
A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
AstraZeneca
Phase 1 Completed
NCT04879589 2023-04-28
Phase 1 Study of ATRS-2002 in Healthy Male Adults
Syneos Health
Phase 1 Withdrawn
NCT04071262 2021-09-21
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT04296578 2021-08-12
Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone
Stanford University
Phase 1 Withdrawn
NCT01574937 2021-08-06
XL-184+Abiraterone in Post-Chemo CRPC
Dana-Farber Cancer Institute
Phase 1 Completed
NCT04889651 2021-07-22
A Study to Compare the Pharmacokinetics and Safety Between BR9004 and BR9004-1 in Healthy Male Volunteers
Boryung Pharmaceutical Co., Ltd
Phase 1 Completed
NCT02730975 2021-01-11
ABIFOOD01
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Phase 1 Completed
NCT02883166 2020-12-07
SNACK
Radboud University Medical Center
Phase 1 Completed
NCT02924766 2020-07-20
A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)
Janssen Research & Development, LLC
Phase 1 Completed
NCT01913015 2017-04-28
Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT02001571 2013-12-05
A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function
Cougar Biotechnology, Inc.
Phase 1 Completed
NCT01664728 2013-04-19
An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001
Janssen Research & Development, LLC
Phase 1 Completed
NCT00910754 2013-04-12
A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Completed
NCT01017939 2013-04-12
A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Completed